In vivo receptor binding of novel α1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia

Life Sciences

Volumn 62, Issue 17-18, 1998, Pages 1585-1589

  Yamada, Shizuo ^a   Ohkura, Takashi ^a   Kimura, Ryohei ^a   Kawabe, Kazuki ^b  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Benign prostatic hyperplasia; In vivo receptor binding; Novel 1 antagonists

Indexed keywords

3 [N [2 (4 HYDROXY 2 ISOPROPYL 5 METHYLPHENOXY)ETHYL] N METHYLAMINOMETHYL] 4 METHOXY 2,5,6 TRIMETHYLPHENOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; SILODOSIN; TAMSULOSIN; UNCLASSIFIED DRUG;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; BINDING COMPETITION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PROSTATE; PROSTATE HYPERTROPHY; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; SPLEEN; SUBMANDIBULAR GLAND; TISSUE DISTRIBUTION;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CRESOLS; INDOLES; MALE; PRAZOSIN; PROSTATE; PROSTATIC HYPERPLASIA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; SULFONAMIDES; TISSUE DISTRIBUTION;

EID: 0032571218     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00111-8     Document Type: Conference Paper

References (19)

1. 1. M. CAINE, S. PERBERG and S. MERETYK, Br. J. Urol. 50 551-554 (1978).
2. 2. A. SHAPIRO, B. MAZOUZ and M. CAINE, Urol. Res. 9 17-20 (1981).
3. 3. H. HEDLUND, E.K. ANDERSSON and A. EK., J. Urol. 130 275-278 (1983).
4. 4. C. HAN, P.W. ABEL and K.P. MINNEMAN, Mol. Pharmacol. 32 505-510 (1987).
5. 5. I. MURAMATSU, T. OHMURA, S. KIGOSHI, S. HASHIMOTO and M. OSHITA, Br. J. Pharmacol. 99 197-201 (1990).
6. 6. J.P. HIEBLE, D.B. BYLUND, D.E. CLARKE, D.C. EIKENBURG, S.Z. LANGER, R.J. LEFKOWITZ, K.P. MINNEMAN and R.R. RUFFOLO, JR., Pharmacol.Rev. 47 267-270(1995).
7. 7. K. HONDA, A. MIYATA-OSAWA, A. TERAI and T. TAKENAKA, Naunyn-Schiedeberg's Arch. Pharmacol. 330 16-21 (1985).
8. 8. R. YAMAGISHI, K. AKIYAMA, S. NAKAMURA, M. HORA, N. MASUDA, A. MATSUZAWA, S. MURATA, A. UJIIE, Y. KURASHINA, K. IIZUKA and M. KITAZAWA, Eur. J. Pharmacol. 315 73-79 (1996).
9. 9. Y. SUZUKI, H. WATANABE, Y. OKAYA, K. AISAKA, R. FUKASAWA, N. MORIYAMA and K. KAWABE, Proc. Int. Continence Soc., 27th Ann. Meeting (1997) (Abstr. 117).
10. 10. S. YAMADA, C. TANAKA, R. KIMURA and K. KAWABE, Life Sci. 54 1845-1854 (1994).
11. 11. M.C. MICHEL and P.A. INSEL, Naunyn-Schmiedeberg's Arch. Pharmacol. 349 136-142 (1994).
12. 12. K. SHIBATA, R. FOLGAR, K. HORIE, K. OBIKA, A. SAKAMOTO, S. OGAWA and G. TSUJIMOTO, Mol. Pharmacol. 48 250-258 (1995).
13. 13. I. MURAMATSU, M. TAKITA, F. SUZUKI, S. MIYAMOTO, S. SAKAMOTO and T. OHMURA, Eur. J. Pharmacol. 300 155-157 (1996).
14. 14. S. UCHIDA, S. YAMADA, T. OHKURA, M. HESHIKIRI, A. YOSHIMI, H. SHIRAHASE and R. KIMURA, Br. J. Pharmacol. 114 217-223 (1995).
15. 15. G. HAN FT and G. Gross, Br. J. Pharmacol. 97 691-700 (1989).
16. 16. R. ABOUD, M, SHAFII and J.R. DOCHERTY, Br. J. Pharmacol. 109 80-87 (1993).
17. 17. K. AKIYAMA, S. TATEMICHI, M. HORA, M. KOJIMA, S. YAMADA, T. OHKURA, R. KIMURA and K. KAWABE, Proc Int. Continence Soc., 27th Ann. Meeting(1997)(Abstr. 101a).
18. 18. C. HAN, P.W. ABEL and K.P. MINNEMAN, Nature 329 333-335 (1987).
19. 19. H. YAZAWA and K. HONDA, Jap J. Pharmacol. 62 297-304 (1993).